Inhibition of protein kinase A and Cyclic AMP response element (CRE)- specific transcription factor binding by Δ9-tetrahydrocannabinol (Δ9- THC): A putative mechanism of cannabinoid-induced immune modulation

Biochemical Pharmacology

Volumn 53, Issue 10, 1997, Pages 1477-1484

  Koh, Woo S ^a   Crawford, Robert B ^a   Kaminski, Norbert E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

CAMP; Cannabinoids; Cascade; CRE; Delta 9 tetrahydrocannabinol; Immune suppression; Protein kinase A

Indexed keywords

ADENYLATE CYCLASE; CANNABINOID RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; DRONABINOL; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; IONOMYCIN; OKT 3; PHORBOL ESTER; TRANS ACTING FACTOR; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; CYCLIC AMP RESPONSIVE ELEMENT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL;

EID: 0030795528     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)82441-0     Document Type: Article

References (40)

1. Mechoulam R, Marihuana chemistry. Science 168: 1159-1160, 1970.
2. Blanchard DK, Newton C, Klein TW, Stewart WE II and Friedman H, In vitro and in vivo suppressive effects of delta-9-tetrahydrocannabinol on interferon production by murine spleen cells. Int J Immunopharmacol 8: 819-824, 1986.
3. Klein T, Kawakami Y, Newton C and Friedman H, Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J Toxicol Environ Health 32: 465-477, 1991.
4. 9-Tetrahydrocanabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function. Immunopharmacology 26: 129-137, 1993.
5. Kaminski NE, Koh WS, Lee M, Yang KH and Kessler FK, Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem Pharmacol 48: 1899-1908, 1994.
6. Friedman H, Shrivers SC and Klein TW, Drugs of abuse and the immune system. In: Immunotoxicology and Immunopharmacology (Eds. Dean J, Luster M, Munson A and Kimber I), pp. 303-322. Raven Press, New York, 1995.
7. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI, Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564, 1990.
8. Munro S, Thomas KL and Abu-Shaar M, Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65, 1993.
9. i in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29: 307-313, 1986.
10. 9-tetrahydrocannabinol in mouse spleen cells: A potential mechanism for cannabinoid-mediated immunosuppression. Life Sci 51: 25-30, 1992.
11. Watson P, Krupinski J, Kempinski A and Frankenfield C, Molecular cloning and characterization of the type VII isoform of mammalian adenylyl cyclase expressed widely in mouse tissues and in S49 mouse lymphoma cells. J Biol Chem 269: 28893-28898, 1994.
12. Pepe S, Ruggiero A, Tortora G, Ciaardiello F, Garbi C, Yokozaki H, Cho-Chung YS, Clair T, Skalhegg BS and Bianco AR, Flow cytometric detection of the RI alpha subunit of type-I cAMP-dependent protein kinase in human cells. Cytometry 15: 73-79, 1994.
13. Russell DH, Type I cyclic AMP-dependent protein kinase as a positive effector of growth. Adv Cyclic Nucleotide Res 9: 493-506, 1978.
14. Hadden JW, Hadden EM, Haddox MK and Goldberg ND, Guanosine 3′:5′-cyclic monophosphates: A possible intracellular mediator of mitogenic influences in lymphocytes. Proc Natl Acad Sci USA 69: 3024-3027, 1972.
15. Smith JW, Steiner AL, Newberry WM and Parker CW, Cyclic adenosine 3′,5′-monophosphate in human lymphocytes. Alteration after phytohemagglutinin. J Clin Invest 50: 432-441, 1971.
16. Laxminarayana D, Berrada A and Kammer GM, Early events of human T lymphocyte activation are associated with type I protein kinase A activity. J Clin Invest 92: 2207-2214, 1993.
17. Kammer GM, The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today 9: 222-229, 1988.
18. Koh WS, Yang KH and Kaminski NE, Cyclic AMP is an essential factor in immune responses. Biochem Biophys Res Commun 206: 703-709, 1995.
19. Riabowol KT, Fink JS, Gilman MZ, Walsh DA, Goodman RH and Feramsco JR, The catalytic subunit of cAMP-dependent protein kinase induces expression of genes containing cAMP-responsive enhancer elements. Nature 336: 83-86, 1988.
20. Deutsch PJ, Hoeffler JP, Jameson L and Habener JF, Cyclic AMP and phorbol ester-stimulated transcription mediated by similar DNA elements that bind distinct proteins. Proc Natl Acad Sci USA 85: 7922-7926, 1988.
21. Gonzalez GA and Montminy MR, Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at Serine 133. Cell 59: 675-680, 1989.
22. Condie R, Herring A, Koh WS, Lee M and Kaminski NE, Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J Biol Chem 271: 13175-13183, 1996.
23. Xie H, Chiles TC and Rothstein TL, Induction of CREB activity via the surface Ig receptor of B cells. J Immunol 151: 880-889, 1993.
24. Montminy MR, Sevarino KA, Wagner JA and Mandel G, Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. Proc Natl Acad Sci USA 83: 6682-6686, 1986.
25. Dunnett CW, A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 50: 1096-1121, 1955.
26. Slipetz DM, O'Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y, Guay D, Labelle M and Metters KM, Activation of the human peripheral cannabinoid receptor results in inhibition of adenlylyl cyclase. Mol Pharmacol 48: 352-361, 1995.
27. Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R and Vogel Z, The peripheral cannabinoid receptor: Adenylate cyclase inhibition and G protein coupling. FEBS Lett 375: 143-147, 1995.
28. Sewing A and Muller R, Protein kinase A phosphorylates cyclin D1 at three distinct sites within the cyclin box and at the C-terminus. Oncogene 9: 2733-2736, 1994.
29. Grieco D, Porcellini A, Avvedimento EV and Gottesman ME, Requirement for cAMP-PKA pathway activation by M phase-promoting factor in the transition from mitosis to interphase. Science 271: 1718-1723, 1996.
30. Barton K, Muthusamy N, Chanyangam M, Fischer C, Clendenin C and Leiden JM, Defective thymocyte proliferation and IL-2 production in transgenic mice expressing a dominant-negative form of CREB. Nature 379: 81-85, 1996.
31. Kaminski NE, Mechanisms of immune modulation by cannabinoids. In: Immunotoxicology and Immunopharmacology (Eds. Dean J, Luster M, Munson A and Kimber I), pp. 349-362. Raven Press, New York, 1995.
32. 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-κB/Rel activation. Mol Pharmacol 50: 334-341, 1996.
33. Novak TJ, White PM and Rothenberg EV, Regulatory anatomy of the murine interleukin-2 gene. Nucleic Acids Res 18: 4523-4533, 1990.
34. Meinkoth JL, Alberts AS, Went W, Fantozzi D, Taylor SS, Hagiwara M, Montminy M and Feramisco JR, Signal transduction through the cAMP-dependent protein kinase. Mol Cell Biochem 127/128: 179-186, 1993.
35. Gonzalez GA, Menzel P, Leonard J, Fischer WH and Montminy MR, Characterization of motifs which are critical for activity of the cyclic AMP-responsive transcription factor CREB. Mol Cell Biol 11: 1306-1312, 1991.
36. Ivashkiv LB, Liou H-C, Kara CJ, Lamph WW, Verma IM and Glimcher LH, mXBP/CRE-BP2 and c-Jun form a complex which binds to the cyclic AMP, but not to the 12-O-tetradecanoylphorbol-13-acetate, response element. Mol Cell Biol 10: 1609-1621, 1990.
37. Hai T and Curran T, Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci USA 88: 3720-3724, 1991.
38. Chen D and Rothenberg E, Molecular basis for developmental changes in interleukin-2 gene inducibility. Mol Cell Biol 13: 228-237, 1993.
39. Novak TJ, Chen D and Rothenberg EV, Interleukin-1 synergy with phosphoinositide pathway agonists for induction of interleukin-2 gene expression: Molecular basis of costimulation. Mol Cell Biol 10: 6325-6334, 1990.
40. Nakano Y, Pross S and Friedman H, Contrasting effect of delta-9-tetrahydrocannabinol on IL-2 activity in spleen and lymph node cells of mice of different ages. Life Sci 52: 41-51, 1993.